NZ740615A - A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site - Google Patents

A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site

Info

Publication number
NZ740615A
NZ740615A NZ740615A NZ74061516A NZ740615A NZ 740615 A NZ740615 A NZ 740615A NZ 740615 A NZ740615 A NZ 740615A NZ 74061516 A NZ74061516 A NZ 74061516A NZ 740615 A NZ740615 A NZ 740615A
Authority
NZ
New Zealand
Prior art keywords
hydrophilic
composition
residence time
fibres
fibre
Prior art date
Application number
NZ740615A
Other languages
English (en)
Inventor
Jens Hansen
Martin Eduardo Santocildes Romero
Original Assignee
Afyx Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afyx Therapeutics As filed Critical Afyx Therapeutics As
Publication of NZ740615A publication Critical patent/NZ740615A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Spinning Methods And Devices For Manufacturing Artificial Fibers (AREA)
  • Nonwoven Fabrics (AREA)
NZ740615A 2015-11-19 2016-11-18 A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site NZ740615A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570745 2015-11-19
PCT/EP2016/078151 WO2017085264A1 (en) 2015-11-19 2016-11-18 A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site

Publications (1)

Publication Number Publication Date
NZ740615A true NZ740615A (en) 2019-06-28

Family

ID=58718438

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ740615A NZ740615A (en) 2015-11-19 2016-11-18 A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site

Country Status (17)

Country Link
US (4) US20180221295A1 (enExample)
EP (1) EP3334412B1 (enExample)
JP (2) JP6606279B2 (enExample)
KR (3) KR20190067280A (enExample)
CN (1) CN108135833B (enExample)
AU (2) AU2016358266B2 (enExample)
BR (1) BR112018001978A2 (enExample)
CA (1) CA2993377C (enExample)
DK (1) DK3334412T3 (enExample)
ES (1) ES2900741T3 (enExample)
IL (1) IL258093B (enExample)
MX (1) MX391778B (enExample)
MY (1) MY167777A (enExample)
NZ (1) NZ740615A (enExample)
RU (2) RU2701513C2 (enExample)
SG (1) SG10201913222XA (enExample)
WO (1) WO2017085264A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887977T3 (es) 2017-01-23 2021-12-29 Afyx Therapeutics As Método para la fabricación de un producto de dos capas a base de fibras electrohiladas
AU2018209592B2 (en) 2017-01-23 2024-03-21 Afyx Therapeutics A/S Method for preparing electrospun fibers with a high content of a bioadhesive substance
WO2021050532A1 (en) * 2019-09-09 2021-03-18 Afyx Therapeutics A/S Compositions for treating fungal infections
JP2022552832A (ja) 2019-10-08 2022-12-20 アフリックス セラピューティクス アー／エス タンパク質の送達のための組成物
EP4121017A4 (en) * 2020-03-17 2024-07-03 Blaesi, Aron H. EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR EXTENDED ACTIVE INGREDIENT RELEASE
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
EP4108231A1 (en) * 2021-06-25 2022-12-28 Johann-Wolfgang-Goethe-Universität Frankfurt am Main In-situ dissolving electrospun polymer fibers for ocular drug delivery
EP4124336B1 (en) * 2021-07-30 2023-10-25 Cannamedical Pharma GmbH Transmucosal patch comprising a cannabinoid and/or an opioid
JP2024542227A (ja) 2021-11-23 2024-11-13 アフリックス デベロップメント アー／エス 粘膜パッチおよびその使用方法
WO2024160792A1 (en) * 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280423A (ja) 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
US6753454B1 (en) * 1999-10-08 2004-06-22 The University Of Akron Electrospun fibers and an apparatus therefor
JP2003521493A (ja) * 2000-01-28 2003-07-15 スミスクライン・ビーチャム・コーポレイション 電気紡糸された医薬組成物
US7309498B2 (en) * 2001-10-10 2007-12-18 Belenkaya Bronislava G Biodegradable absorbents and methods of preparation
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
TW200410714A (en) * 2002-08-07 2004-07-01 Smithkline Beecham Corp Electrospun amorphous pharmaceutical compositions
AU2003265446A1 (en) * 2002-08-13 2004-02-25 Medtronic, Inc. Active agent delivery system including a hydrophilic polymer, medical device, and method
EP2271301A4 (en) * 2008-03-27 2014-07-02 Agigma Inc METHOD AND COMPOSITIONS FOR THE DELIVERY OF FUNDS
US20130295143A1 (en) * 2012-05-02 2013-11-07 Massachusetts Institute Of Technology Electroprocessing of active pharmaceutical ingredients
CN102670483B (zh) * 2012-05-09 2014-04-02 上海交通大学 一种用于高血脂症治疗的静电纺丝纤维膜制剂及其制备方法
WO2014066297A1 (en) * 2012-10-22 2014-05-01 North Carolina State University Nonwoven fiber materials
EP2810645B1 (en) * 2013-06-06 2017-05-24 A. Sezai Sarac New Drug Delivery System
CA2950821C (en) 2014-06-10 2024-02-06 Dermtreat Aps Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa

Also Published As

Publication number Publication date
MY167777A (en) 2018-09-25
AU2016358266A1 (en) 2018-04-05
EP3334412B1 (en) 2021-10-20
CA2993377A1 (en) 2017-05-26
HK1256209A1 (en) 2019-09-13
RU2701513C2 (ru) 2019-09-27
KR20190020173A (ko) 2019-02-27
DK3334412T3 (da) 2022-01-17
CA2993377C (en) 2019-11-12
AU2018220020A1 (en) 2018-09-06
JP2018528256A (ja) 2018-09-27
US20240139117A1 (en) 2024-05-02
KR102001163B1 (ko) 2019-07-18
KR102435996B1 (ko) 2022-08-25
WO2017085264A1 (en) 2017-05-26
RU2018109496A (ru) 2019-09-19
AU2016358266B2 (en) 2018-06-21
US20180221295A1 (en) 2018-08-09
ES2900741T3 (es) 2022-03-18
RU2019129082A (ru) 2020-04-28
EP3334412A1 (en) 2018-06-20
US20230285313A1 (en) 2023-09-14
JP6606279B2 (ja) 2019-11-13
KR20180040704A (ko) 2018-04-20
CN108135833A (zh) 2018-06-08
US20190254985A1 (en) 2019-08-22
BR112018001978A2 (pt) 2018-09-18
MX2018005206A (es) 2018-08-01
SG10201913222XA (en) 2020-03-30
JP6929916B2 (ja) 2021-09-01
AU2018220020C1 (en) 2020-09-17
RU2018109496A3 (enExample) 2019-09-19
IL258093A (en) 2018-05-31
KR20190067280A (ko) 2019-06-14
IL258093B (en) 2022-03-01
CN108135833B (zh) 2022-11-29
MX391778B (es) 2025-03-21
JP2020022787A (ja) 2020-02-13
AU2018220020B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
NZ740615A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
SG10201808743VA (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112018073703A2 (pt) emplastro para pele ou ferida, composição farmacêutica e método para a liberação de uma substância ativa
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
BR112015022566A2 (pt) composto e composição farmacêutica
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
MX382580B (es) Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos.
EP4238580A3 (en) Transdermal delivery system including an interface mediator
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX2015017202A (es) Formulacion de liberacion modificada.
WO2016040814A3 (en) Disulfide polymers and methods of use
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
CL2018003682A1 (es) Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos.
BR112015022134A2 (pt) composto, composição farmacêutica, adesivo, bastão, dispensador de spray, tubo ou caneta, e, método de tratamento de uma infecção
MX2018009739A (es) La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas.
HK1223852A1 (zh) 睪丸酮凝膠組合物及相關方法
TR201903234T4 (tr) Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2021 BY CPA GLOBAL

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2022 BY CPA GLOBAL

Effective date: 20211007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2023 BY CPA GLOBAL

Effective date: 20221007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2024 BY CPA GLOBAL

Effective date: 20231006

LAPS Patent lapsed